Eloralintide
Eloralintide (LY3841136)
Also known as: LY3841136
Lilly's selective amylin agonist that reached about 20% weight loss in Phase 2 with milder gut side effects than GLP-1 drugs, now in Phase 3 alone and as an add-on to tirzepatide.
Overview
Eloralintide is a once-weekly amylin receptor agonist with no direct GLP-1 activity. In a 48-week Phase 2 study of 263 adults with obesity, weight loss ranged from 9.5% to 20.1% across doses against 0.4% on placebo, with gastrointestinal tolerability that looked better than the GLP-1 class. Lilly moved it into the ENLIGHTEN Phase 3 program in late 2025 and is separately testing it on top of tirzepatide, positioning it as the company's designated add-on for people who plateau on incretin drugs.
Mechanism of action
Activates amylin receptors (calcitonin receptor plus RAMP complexes), slowing gastric emptying and reducing appetite through a pathway that is independent of GLP-1.
Key studies & citations
- Human2025
Eloralintide, a selective amylin receptor agonist, in adults with obesity: a phase 2 trial
9.5% to 20.1% weight loss at 48 weeks versus 0.4% on placebo.
The Lancet - Human2025
ENLIGHTEN-1: eloralintide in adults with obesity (Phase 3)
Pivotal program recruiting since late 2025.
ClinicalTrials.gov NCT07321886 - Human2026
ENLIGHTEN-6: eloralintide added to tirzepatide
Tests the amylin plus incretin combination in one program.
ClinicalTrials.gov NCT07392190
Frequently asked questions
How is eloralintide different from cagrilintide?
Both are long-acting amylin agonists. Eloralintide is engineered for selectivity at amylin receptors and was studied alone first, whereas cagrilintide is mostly developed inside the CagriSema combination with semaglutide.
Is eloralintide available?
No. It is in Phase 3 trials and cannot be prescribed anywhere.